Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
ID: 344596Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/344596

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-025.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)" under the Department of Health and Human Services. This initiative invites applications for ancillary studies that enhance ongoing clinical projects, particularly those aligned with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), utilizing existing patient samples and data while ensuring the integrity of the parent project. Funding of up to $300,000 per year is available for projects lasting no more than four years, with an emphasis on collaborative approaches and the involvement of junior investigators. Interested applicants must submit their proposals by December 5, 2025, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-025.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Funding Opportunity Announcement (FOA) titled "Ancillary Studies to Ongoing Clinical Projects" (PAR-23-025). This initiative aims to solicit applications for conducting timely ancillary studies that enhance ongoing clinical projects related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The FOA encourages researchers to leverage existing clinical trials or studies to explore additional research questions using already available patient samples and data, all while maintaining the integrity of the parent project. Applicants must demonstrate the time-sensitive nature of their studies and enlist cooperation from parent project leadership. Funding is available up to $300,000 per year for projects not exceeding four years, with a focus on collaborative approaches and involving junior investigators. Specific instructions are provided regarding application submission, compliance with NIH grant policies, and eligibility criteria, emphasizing the requirement for scientific merit and the enhancement of the parent project's value. This FOA reflects NIH's commitment to optimizing resource use in clinical research and advancing our understanding of diseases within the NIAMS portfolio.
    Similar Opportunities
    Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Ancillary Studies to Ongoing Clinical Projects" grant (FON: PAR-24-289), aimed at supporting time-sensitive ancillary studies that leverage existing resources from active clinical projects related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This funding opportunity encourages innovative research that enhances the scientific content of parent projects, with eligible studies potentially including interventional trials or observational studies that utilize well-characterized cohorts, data, and biological samples. The total budget for direct costs is capped at $300,000 per year, with projects lasting a maximum of four years, and applications must be submitted electronically by September 5, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Ancillary Studies to Ongoing Clinical Projects" funding opportunity through the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support time-sensitive ancillary studies related to active interventional clinical trials or observational studies, enhancing scientific understanding in alignment with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Eligible applicants include a diverse range of institutions, with a budget cap of $400,000 over two years, and projects must demonstrate time sensitivity and integration with existing studies. Interested parties can find more information and application guidelines at the NIH website, with a submission deadline of December 5, 2025.
    Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) grant, aimed at facilitating time-sensitive ancillary studies related to ongoing clinical projects under the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This initiative allows applicants to explore new research questions not addressed in parent studies, utilizing existing resources and patient cohorts to enhance scientific understanding and potentially improve diagnostics and treatments for diseases within the NIAMS portfolio. Eligible applicants include higher education institutions, nonprofits, and government agencies, with a funding ceiling of $250,000 per year and a total request limit of $400,000 over two years. Applications are due by December 5, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies focused on musculoskeletal, rheumatic, and skin diseases, under the grant title PAR-24-036. This grant, which does not allow clinical trials, aims to support observational studies that collect critical data to inform future clinical research, particularly regarding disease symptoms, progression, and participant eligibility, while also exploring telehealth and digital outcomes. The initiative is designed to enhance the rigor of future clinical trials through comprehensive data collection from diverse populations, ultimately improving patient outcomes in affected communities. The grant provides up to $475,000 over four years, with applications opening on February 4, 2024, and funding decisions expected by late 2024. Interested applicants can find more information and guidelines at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases under the R01 Research Project Grant program. This initiative aims to support observational studies that gather critical data to inform future clinical research, focusing on understanding disease symptoms, progression, participant recruitment strategies, and potential biomarkers. The funding opportunity is significant for enhancing research outcomes in health fields related to these diseases, with applicants eligible to request up to $475,000 over four years. Key deadlines include an application submission start date of February 4, 2025, and a final expiration date of November 3, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), is offering a funding opportunity for the implementation of interventional clinical trials via the Clinical Trial Implementation Cooperative Agreement (UG3/UH3). This initiative aims to support investigation-driven projects for both single and multi-site trials across all phases, emphasizing the importance of preliminary planning and the completion of necessary approvals before trial execution. The funding opportunity reflects NIAMS' commitment to advancing research in arthritis and musculoskeletal diseases, with grants of up to $250,000 available for the UG3 phase and no specific limit for UH3 project budgets, designed for up to six years of support. Interested applicants can find more information and application details at the provided link, with the application deadline set for March 4, 2027.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding opportunities through the "Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases" program, specifically under the R61 Clinical Trial mechanism. This initiative aims to support short-term exploratory clinical trials that investigate treatments for rheumatic, musculoskeletal, and skin conditions, with a focus on diverse therapeutic approaches. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and state and local governments, with a maximum budget of $600,000 for a three-year project, not exceeding $300,000 in any single year. Applications must be submitted electronically via Grants.gov, with key deadlines starting from February 4, 2024, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Clinical Trial Grants (R61) to support research in arthritis and musculoskeletal and skin diseases. This funding opportunity aims to facilitate short-term, interventional studies that address critical research questions, particularly those evaluating drug efficacy in rare diseases, without requiring preliminary data. Grants can provide up to $600,000 over three years, with applications due by November 2, 2026. Interested applicants are encouraged to consult with NIH staff during the application process and can find additional information at NIH Grants or by contacting NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: Small Grant Program for NIAMS K01, K08, K23, and K25 Recipients (R03) (Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Limited Competition Small Grant Program (R03) aimed at supporting recipients of K01, K08, K23, and K25 awards from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This program allows eligible awardees, specifically those in their second to fourth award year who do not yet hold independent R01 grants, to request up to $100,000 in direct costs over a two-year period to enhance their research capabilities, focusing on pilot studies, methodology development, and secondary data analysis, while explicitly excluding clinical trials. The initiative is designed to foster the development of early-career scientists and strengthen the research landscape by generating additional publications and data necessary for future R01 grant applications. Interested applicants must submit their proposals by February 19, 2025, and can find more information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.